Insight journal - Company

Abbott Laboratories focus on CNS and oncology: Pharma partnering activity 2005-2013

Posted on 22 February 2013

Tags: ,

Abbott Laboratories announced over 130 pharma partnering / licensing deals since 2005, with over 25 deals in 2012 alone.

Abstracted from: Partnering Deals and Alliances with Abbott Laboratories

The number of pharma partnering, collaborative R&D and licensing deals announced varied year on year with a significant dip in 2011 before a resurgence in 2012, with 25 deals announced. This was probably due to significant reorganization internal to the company prior to the split of the company into Abbott Laboratories and Abbvie in October 2011.

The following figure shows the level of Abbott partnering deal announcements since 2005.

Figure 1: Abbott partnering deals 2005-2012

Abbott Laboratories partnering deals 2005-2012

Abbott Laboratories partnering deals 2005-2012

Source: Current Agreements, 2013

An analysis of all the pharma partnering deals shows a strong emphasis on partnerships in cardiovascular, cancer, followed by infectives, central nervous system, genitourinary and metabolic diseases. This reflects the focus areas of Abbott strongly.

The following table provides an overview of the partnering deals announced by Abbott based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Deals and Alliances with Abbott Laboratories

Figure 2: Abbott partnering deals by therapy area 2005-2013

Abbott partnering deals by therapy 2005-2013

Abbott partnering deals by therapy 2005-2013

Source: Current Agreements, 2013

Further analysis of these pharma partnering deals shows that Abbott has a preference for collaborative R&D, development and licensing deals, similar to many other top pharmaceutical or big pharma companies. Such partnering deals provide the right for Abbott to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Abbott based on deal type disclosed.

Figure 3: Abbott partnering deals by deal type 2005-2013

Abbott partnering deals by deal type 2005-2013

Abbott partnering deals by deal type 2005-2013

Source: Current Agreements, 2013

When looking at stage of development at partnering deal signing, the most popular stage at signing is marketed with 39 deal announcements.

Discovery stage deals dominated the deals pre-commercialization with 23 collaborative R&D deal announcements.

Abbott is also active in pharma partnering at preclinical, phase I, phase II and phase III stage deals. Such deals are of on-going importance to all top pharmaceutical companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.

The following table provides an overview of the partnering deals announced by Abbott based on stage of development at signature.

Figure 4: Abbott partnering by stage of development 2005-2013

Abbott partnering deals by stage of development 2005-2013

Abbott partnering deals by stage of development 2005-2013

Source: Current Agreements, 2013

Abbott Laboratories has signed over 130 pharma partnering, collaborative R&D and licensing deals since 2005. The following provides a summary of the top deals by headline value.

Figure 5: Top Abbott partnering deals by headline value 2005-2013

Top Abbott partnering deals by headline value

Top Abbott partnering deals by headline value

Source: Current Agreements, 2013

Our report provides more detailed insight into the details of each deal. See: Partnering Deals and Alliances with Abbott Laboratories

More

Summary profile data for Abbott

Partnering interests for Abbott

M&A activity for Abbott

 

Abbott partnering at Current Agreements

View all partnering deals for Abbott: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Deals and Alliances with Abbott Laboratories

 

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Abbott Laboratories

Report: Partnering Deals and Alliances with Big Pharma

 

Available resources for deal coverage for Abbott

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Abbott company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Print Friendly, PDF & Email

Leave a Reply